Therapeutic Window of Lamotrigine for Mood Disorders: A Naturalistic Retrospective Study

Abstract

Introduction: Lamotrigine is widely used for mood disorders including bipolar disorder and major depression, but its therapeutic levels have yet to be determined. This study was conducted to investigate the hypothesis that lamotrigine may have a therapeutic window for mood disorders.

Methods: 25 patients with mood disorders received lamotrigine for more than one year during which time plasma lamotrigine levels were measured at least once. Their mental state was retrospectively and regularly but blindly assessed using the Clinical Global Impression–Severity (CGI-S) scale. In order to investigate our hypothesis, we depicted the relationship between the last lamotrigine levels and the last CGI scores in 25 patients. If any, the potential therapeutic window was further investigated.

Results: The relationship between the last lamotrigine levels and the last CGI scores in the 25 patients indicated the presence of a therapeutic window of lamotrigine from 5 to 11 μg/mL. The repeated measures of ANOVA reached a significant tendency of the effects of lamotrigine levels within 5–11 μg/mL on better CGI-S scores, and the CGI-S scores at the last observation of the 15 patients whose lamotrigine levels were within 5–11 μg/mL were significantly better than those of 10 patients whose lamotrigine levels were not within 5–11 μg/mL.

Conclusion: These findings suggest that lamotrigine may have a therapeutic window for patients with mood disorder from 5 to 11 μg/mL.

Key words

lamotrigine - therapeutic levels - mood disorders

• References

• 1 Calabrese JR, Bowden CL, Sachs GS et al. Lamictal 602 Study Group. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry 1999; 60: 79-88
• 2 Calabrese JR, Huffman RF, White RL et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disord 2008; 10: 323-333
• 3 Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry 2009; 194: 4-9
• 4 Ketter TA, Brooks JO, Hoblyn JC et al. Effectiveness of lamotrigine in bipolar disorder in a clinical setting. J Psychiatr Res 2009; 43: 13-23
• 5 Bowden CL, Calabrese JR, Sachs G et al. Lamictal 606 Study Group . A placebo controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003; 60: 392-400
• 6 Calabrese JR, Bowden CL, Sachs GS et al. Lamictal 605 Study Group . A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003; 64: 1013-1024
• 7 Goodwin GM, Bowden CL, Calabrese JR et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 2004; 65: 432-441
• 8 Popovic D, Reinares M, Amann B et al. Number needed to treat analysis of drugs used for maintenance treatment of bipolar disorder. Psychopharmacology 2011; 213: 657-667
• 9 Reid JG, Gitlin MJ, Altshuler LL. Lamotrigine in psychiatric disorders. J Clin Psychiatry 2013; 74: 675-684
• 10 Hiemke C, Baumann P, Bergelmann N et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 2011; 44: 195-235
• 11 Guy W. (ed.) Clinical Global Impressions. In: ECDEU Assessment Manual for Psychopharmacology, revised. National Institute of Mental Health; Rockville, MD: 1976